ReviewClinical drug investigation2017

Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.

Zeyu Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.